Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Viable pregnancy assessed by Doppler~2. Gestational age 16 to 32 weeks (inclusive) by fundal height~3. No history of IPTp use during this pregnancy~4. Willing to participate and complete the study schedule~5. Willing to sign or thumb print informed consent~6. Resident of study area and intending to stay in the area for the duration of the follow-up~7. Willing to deliver in the labor ward of the study clinic or hospital~8. HIV negative at enrolment~Exclusion Criteria:~1. HIV positive or unknown~2. Residence outside study area or planning to move out in the 12 months following enrolment~3. High risk pregnancy, including any pre-existing illness likely to cause complication of pregnancy (hypertension, diabetes, asthma, epilepsy, renal disease, liver disease, fistula repair, leg or spine deformity)~4. Severe anemia requiring blood transfusion (Hb ≤ 7.0 g/dL) at enrolment~5. Known allergy or previous adverse reaction to any of the study drugs~6. Unable to give informed consent (for example due to mental disability)~7. Previous inclusion in the same study~8. Gestational age \>32 weeks~9. Previous IPTp during the current pregnancy~10. Participating in other malaria intervention studies~11. Known or suspected cardiac disease~12. Patients taking drugs in any of the following classes: antiarrhythmic agents, neuroleptics, macrolides, and certain antimalarial drugs such as mefloquine, chloroquine, halofantrine and lumefantrine.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IPTp-DP (Type: EXPERIMENTAL): At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
- ISTp-DP (Type: EXPERIMENTAL): At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
- IPTp-SP (Type: ACTIVE_COMPARATOR): Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).